Methods Of Treating Pulmonary Arterial Hypertension
Patent No. EP4065119 (titled "Methods Of Treating Pulmonary Arterial Hypertension") was filed by Actelion Pharmaceuticals on Nov 27, 2020. The application was issued on Sep 4, 2024.
Patent Summary
Initial combination therapy of macitentan, tadalafil, and selexipag for treating pulmonary arterial hypertension (PAH) with a unique dosing regimen. The therapy combines the endothelin receptor antagonist macitentan, phosphodiesterase type 5 inhibitor tadalafil, and prostacyclin receptor agonist selexipag, with macitentan and tadalafil initiated on day 1 and selexipag on day 15 ± 3 days. This regimen achieves significant hemodynamic and functional improvements in newly diagnosed PAH patients, with a notable reduction in pulmonary vascular resistance and improvement in right heart function.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4065119
- Application Number
- EP20820054A
- Filing Date
- Nov 27, 2020
- Status
- Granted And Under Opposition
- Aug 2, 2024
- Publication Date
- Sep 4, 2024
- External Links
- Slate, Register , Google Patents